Ireland's Elan Corp has inked a deal with Ingenium Pharmaceuticals
of Germany that will see the companies apply Ingenium's functional
genomics technologies to the discovery and development of novel
therapeutics for pain...
British Biotech, once the darling of the UK biotechnology industry
but now suffering the after-effects of a string of major drug
development failures, is having another go at bolstering its
pipeline via a merger with fellow UK company...
Losses continue for buccal drug delivery company Generex
Biotechnology with the company yesterday reporting a net loss of
$4.6 million (€4.3m), or $(27) per share for the quarter ended
January 31, 2003 - compared to a net loss of...
Akzo Nobel has opened a new powder coatings factory in Ho Chi Minh
City, Vietnam in partnership with Chang Cheng Securities, marking
the 12th powder coatings site in the Asia Pacific region for the
SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company
German pharmaceutical company Boehringer Ingelheim has signed a
long-term agreement with software company MDL Information Systems
to use its software technology for managing and deploying chemical
Applied Biosystems group, the world's number one maker of
gene-analysing equipment, warned on Tuesday that it would report
lower-than-expected fiscal third-quarter revenue and earnings due
to deteriorating business conditions.
Strong sales from its life science unit helped US biotechnology
company Enzo Biochem, that specialises in gene identification
technologies, post total revenues of $13.1 million, compared with
$11.8 million in the corresponding year...
Drug target validation has become the critical step in maintaining
profitability for the pharmaceutical industry, claims a new report
from market research company Business Communications. Drug
developers must accelerate identification...
"The current confluence of negative factors facing the chemical
manufacturing industry could be called 'the perfect storm',"
said Andrew N. Liveris, president of Dow Chemical company's
Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...